XML 51 R39.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Revenue recognition (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | The Company's revenues disaggregated by operating segment and major sources for the three and six months ended June 30, 2024 and 2023 were as follows:
| Three Months Ended June 30, 2024 |  | Three Months Ended June 30, 2023
| USG |  | Non-USG |  | Total |  | USG |  | Non-USG |  | Total
Commercial Product sales | $ | 0.1 |  |  | $ | 119.9 |  |  | $ | 120.0 |  |  | $ | 0.3 |  |  | $ | 137.6 |  |  | $ | 137.9 |
MCM Product sales | 30.6 |  |  | 32.8 |  |  | 63.4 |  |  | 150.2 |  |  | 14.1 |  |  | 164.3 |
Bioservices: |  |  |  |  |  |  |  |  |  |  |
Services (1) | — |  |  | 64.5 |  |  | 64.5 |  |  | — |  |  | 26.4 |  |  | 26.4 |
Leases | — |  |  | 0.2 |  |  | 0.2 |  |  | — |  |  | 2.7 |  |  | 2.7 |
Total Bioservices | $ | — |  |  | $ | 64.7 |  |  | $ | 64.7 |  |  | $ | — |  |  | $ | 29.1 |  |  | $ | 29.1 |
Contracts and grants | 6.6 |  |  | — |  |  | 6.6 |  |  | 4.6 |  |  | 2.0 |  |  | 6.6 |
Total revenues | $ | 37.3 |  |  | $ | 217.4 |  |  | $ | 254.7 |  |  | $ | 155.1 |  |  | $ | 182.8 |  |  | $ | 337.9 |
(1) Bioservices Services revenues for the three months ended June 30, 2024 include $50.0 million attributable to the confidential arbitration settlement (the “Settlement Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, related to the 2022 termination of manufacturing services agreement with Janssen (the “Janssen Agreement”). The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, “Litigation” for additional information related to the accounting treatment and settlement of the arbitration with Janssen.
| Six Months Ended June 30, 2024 |  | Six Months Ended June 30, 2023
| USG |  | Non-USG |  | Total |  | USG |  | Non-USG |  | Total
Commercial Product sales | $ | 0.4 |  |  | $ | 238.1 |  |  | $ | 238.5 |  |  | $ | 0.3 |  |  | $ | 243.8 |  |  | $ | 244.1 |
MCM Product sales | 144.7 |  |  | 74.1 |  |  | 218.8 |  |  | 176.3 |  |  | 25.2 |  |  | 201.5 |
Bioservices: |  |  |  |  |  |  |  |  |  |  |
Services (1) | — |  |  | 82.8 |  |  | 82.8 |  |  | — |  |  | 39.0 |  |  | 39.0 |
Leases | — |  |  | 0.4 |  |  | 0.4 |  |  | — |  |  | 4.5 |  |  | 4.5 |
Total Bioservices | $ | — |  |  | $ | 83.2 |  |  | $ | 83.2 |  |  | $ | — |  |  | $ | 43.5 |  |  | $ | 43.5 |
Contracts and grants | 14.0 |  |  | 0.6 |  |  | 14.6 |  |  | 9.5 |  |  | 3.6 |  |  | 13.1 |
Total revenues | $ | 159.1 |  |  | $ | 396.0 |  |  | $ | 555.1 |  |  | $ | 186.1 |  |  | $ | 316.1 |  |  | $ | 502.2 |
(1) Bioservices Services revenues for the six months ended June 30, 2024 include $50.0 million attributable to the Settlement Agreement. The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, “Litigation” for additional information related to the Settlement Agreement and its accounting treatment.
Schedule of Rollforward of Contract Liabilities | The following table presents the roll forward of the contract liability balances:
|  | Contract Liabilities
Balance at December 31, 2023 |  | $ | 29.9 |
Balance at June 30, 2024 |  | $ | 9.7 |
Revenue recognized in the period from amounts included in contract liability at the beginning of the period: |  | $ | 25.0 |
Schedule of Accounts Receivable, Net | Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:
|  | June 30, 2024 |  | December 31, 2023
Accounts receivable: |  |  |  |
Billed |  | $ | 120.7 |  |  | $ | 141.8 |
Unbilled |  | 82.5 |  |  | 51.4 |
Allowance for expected credit losses |  | (6.9) |  |  | (2.2) |
Accounts receivable, net |  | $ | 196.3 |  |  | $ | 191.0 |

X
- Definition Schedule Of Accounts Receivable, Net [Table Text Block] + References No definition available. + Details
Name: | ebs_ScheduleOfAccountsReceivableNetTableTextBlock
Namespace Prefix: | ebs_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration